363
Views
16
CrossRef citations to date
0
Altmetric
Original Articles

Comparison of Subtenon Triamcinolone Acetonide Injection with Topical Nepafenac for the Treatment of Pseudophakic Cystoid Macular Edema

, MD, , MD, , MD, , MD, & , MD
Pages 513-519 | Received 14 Oct 2015, Accepted 25 Jan 2016, Published online: 25 Mar 2016

REFERENCES

  • Henderson BA, Kim JY, Ament CS, et al. Clinical pseudophakic cystoid macular edema. Risk factors for development and duration after treatment. J Cataract Refract Surg. 2007;33:1550–1558.
  • Fenicia V, Balestrieri M, Perdicchi A, et al. Intravitreal injection of dexamethasone implant and ranibizumab in cystoid macular edema in the course of Irvine-Gass syndrome. Case Rep Ophthalmol. 2014;5:243–248.
  • Al Zamil WM. Short term safety and efficacy of intravitreal 0. 7-mg dexamethasone implants for pseudophakic cystoid macular edema. Saudi J Ophthalmol. 2015;29:130–134.
  • Hariprasad SM, Akduman L, Clever JA, et al. Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0. 1%. Clin Ophthalmol. 2009;3:147–154.
  • Ruiz RS, Saatci OA. Visual outcome in pseudophakic eyes with clinical cystoid macular edema. Ophthalmic Surg. 1991;22:190–193.
  • Matsuura K, Uotani R, Terasaka Y. Subtenon triamcinolone injection for postoperative cystoid macular edema associated with tafluprost. Clin Ophthalmol. 2013;7:1525–1528.
  • Kanski JJ, Bowling B. Clinical Ophthalmology: A Systematic Approach. Edinburgh: Elsevier Saunders 2011:296–298.
  • Warren KA, Fox JE. Topical nepafenac as an alternate treatment for cystoid macular edema in steroid responsive patients. Retina. 2008;28:1427–1434.
  • Matsuura K, Sasaki S, Uotani R. Successful treatment of prostaglandin-induced cystoid macular edema with subtenon triamcinolone. Clin Ophthalmol. 2012;6:2105–2108.
  • Guo S, Patel S, Baumrind B, et al. Management of pseudophakic cystoid macular edema. Surv Ophthalmol. 2015;60:123–137.
  • Barge S, Rothwell R, Sepúlveda P, et al. Intravitreal and subtenon depot triamcinolone as treatment of retinitis pigmentosa associated cystoid macular edema. Case Rep Ophthalmol Med. 2013;2013:591–681.
  • Dang Y, Mu Y, Li L, et al. Comparison of dexamethasone intravitreal implant and intravitreal triamcinolone acetonide for the treatment of pseudophakic cystoid macular edema in diabetic patients. Drug Des Devel Ther. 2014;18:1441–1449.
  • Venkatesh P, Kumar CS, Abbas Z, et al. Comparison of the efficacy and safety of different methods of posterior subtenon injection. Ocul Immunol Inflamm. 2008;16:217–223.
  • Byun YS, Park YH. Complications and safety profile of posterior subtenon injection of triamcinolone acetonide. J Ocul Pharmacol Ther. 2009;25:159–162.
  • Nardi M. Nepafenac in the prophylaxis and treatment of pain, and ocular inflammation after cataract surgery and in the prophylaxis of postoperative macular edema in diabetic patients. Eur Ophthalmol Rev. 2012;6:169–172.
  • Warren KA, Bahrani H, Fox JE. NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. Retina. 2010;30:260–266.
  • Sukhija J, Dogra MR, Ram J, et al. Acute orbital abscess complicating deep posterior subtenon triamcinolone injection. Indian J Ophthalmol. 2008;56:246–247.
  • Hashizume K, Nabeshima T, Fujiwara T, et al. A case of herpetic epithelial keratitis after triamcinolone acetonide subtenon injection. Cornea. 2009;28:463–464.
  • Mueller AJ, Jian G, Banker AS, et al. The effect of deep posterior subtenon injection of corticosteroids on intraocular pressure. Am J Ophthalmol. 1998;125:158–163.
  • Feiz V, Oberg TJ, Kurz CJ, et al. Nepafenac-associated bilateral corneal melt after photorefractive keratectomy. Cornea. 2009;28:948–950.
  • Di Pascuale MA, Whitson JT, Mootha VV. Corneal melting after use of nepafenac in a patient with chronic cystoid macular edema after cataract surgery. Eye Contact Lens. 2008;34:129–130.
  • Reis A, Bimbaum F, Hansen LL, et al. Successful treatment of macular edema with valdecoxib. J Cataract Refract Surg. 2007;33:682–685.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.